Every Form 4 that Zura Bio Limited (ZURA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ZURA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZURA filings page.
Zura Bio Ltd director Jennifer Jarrett received a grant of share options covering 51,000 Class A Ordinary Shares. The options have an exercise price of $3.62 per share and expire on June 17, 2036. Following this grant, she holds options on 51,000 shares directly.
The option award vests in twelve substantially equal monthly installments over one year starting June 17, 2026. Any remaining unvested portion will vest immediately before the next annual shareholder meeting after the grant date, subject to her continued service through each vesting date.
Zura Bio Ltd director Parvinder Thiara received a grant of share options covering 51,000 Class A Ordinary Shares. The options have an exercise price of $3.62 and expire on June 17, 2036. They vest in twelve roughly equal monthly installments starting June 17, 2026, with any remaining unvested portion vesting just before the next annual shareholder meeting, subject to continued service.
Zura Bio Ltd director Steven J. Schoch received a grant of stock options as compensation. The award covers 51,000 options to buy Class A Ordinary Shares at an exercise price of $3.62 per share, expiring on June 17, 2036. The option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026, with any remaining unvested portion vesting immediately before the next annual meeting of shareholders, subject to his continued service.
Zura Bio Ltd director Ajay Nirula received a grant of share options covering 51,000 Class A Ordinary Shares. The options have an exercise price of $3.62 per share and expire on June 17, 2036. They vest in twelve substantially equal monthly installments over one year starting June 17, 2026, with any remaining unvested portion vesting the day before the next annual shareholder meeting, subject to his continued service. No common shares were bought or sold; this filing reflects a compensation-related award.
Zura Bio Ltd director Amit Munshi received an option grant for 51,000 shares of Class A Ordinary Shares. The option has an exercise price of $3.62 per share and expires on June 17, 2036. It vests in twelve substantially equal monthly installments over one year starting June 17, 2026, with any remaining unvested portion vesting immediately before the next annual shareholder meeting, contingent on continued service.
Zura Bio Ltd director Mark Eisner received a grant of share options for 51,000 Class A Ordinary Shares. The options have an exercise price of $3.62 per share and expire on June 17, 2036. This is a compensation-related award, not an open-market purchase or sale.
The option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026, subject to his continued service. Any remaining unvested portion will vest on the day immediately before the next annual meeting of shareholders following the grant date. After this award, Eisner holds 51,000 options directly.
Zura Bio Ltd director Daniel J. Becker received a grant of 51,000 stock options on June 17, 2026. These options allow him to buy Class A Ordinary Shares at an exercise price of $3.62 per share and expire on June 17, 2036.
According to the terms, the award vests in twelve substantially equal monthly installments over one year starting June 17, 2026. Any remaining unvested portion will vest immediately before the next annual meeting of shareholders, as long as he continues in service through each vesting date.
Zura Bio Ltd reported that Chief Technology Officer Gary Whale received an employee share option grant covering 263,000 Class A Ordinary Shares. The options have an exercise price of $6.03 per share and expire on April 1, 2036.
These options were granted as a compensation award rather than an open-market purchase. One fourth of the shares will vest on April 1, 2027, with the remaining options vesting in equal quarterly installments over time, subject to his continuous service.
Zura Bio Ltd reported that officer Kiran Nistala received an option grant for 340,900 Employee Share Options to buy Class A Ordinary Shares at an exercise price of $6.03 per share. These options expire on April 1, 2036 and represent compensation rather than a market purchase.
According to the vesting terms, one fourth of the options will vest on April 1, 2027, with one twelfth of the remaining options vesting in equal quarterly installments thereafter, as long as Nistala continues in service. After this grant, Nistala holds 340,900 derivative securities directly related to this award.
Zura Bio Ltd Chief Financial Officer Eric J. Hyllengren received an employee stock option grant covering 340,900 Class A Ordinary Shares. The option has an exercise price of $6.03 per share and expires on April 1, 2036. This is a compensation-related award, not an open‑market purchase.
According to the vesting schedule, one fourth of the option vests on April 1, 2027, with the remaining three fourths vesting in equal quarterly installments thereafter, subject to his continuous service. Following this grant, he holds options for 340,900 shares directly.
Zura Bio Ltd reported that its Chief Legal Officer, Davis Kim, received an employee stock option grant covering 425,700 Class A Ordinary Shares. The options have an exercise price of $6.03 per share and expire on April 1, 2036.
According to the vesting terms, one fourth of the option award vests on April 1, 2027, with the remaining options vesting in equal quarterly installments thereafter, contingent on Kim’s continued service. This is a compensation-related award rather than an open-market share purchase or sale.
Zura Bio Ltd reported that Chief Executive Officer Sandeep Chidambar Kulkarni received an award of employee share options covering 894,000 Class A Ordinary Shares. The options have an exercise price of 6.03 per share and expire on April 1, 2036.
According to the vesting terms, one fourth of the options will vest on April 1, 2027, and the remaining three fourths will vest in equal quarterly installments thereafter, contingent on his continuous service. Following this grant, he holds 894,000 options directly.
Nirula Ajay reported acquisition or exercise transactions in this Form 4 filing.
Zura Bio Ltd director Ajay Nirula reported receiving a grant of 37,812 share options. These options were awarded on February 21, 2026 and vest in twelve substantially equal monthly installments over one year starting from that date. Any remaining unvested options will vest on the day immediately before the next annual meeting of shareholders following the grant date, as long as he continues in service through each vesting date.
Zura Bio Ltd reported that affiliated entity AI Biotechnology LLC, a 10% owner, bought 2,000,000 Class A Ordinary Shares of Zura Bio.
The shares were acquired at $6.25 per share in a registered offering by the company, increasing AI Biotechnology LLC’s direct holdings to 6,552,725 shares. Related entities, including Access Industries Holdings LLC, Access Industries Management, LLC and Len Blavatnik, may be deemed beneficial owners through their control structure but each disclaims beneficial ownership beyond any pecuniary interest.
Zura Bio Ltd director Mark Eisner received a grant of options to acquire 37,812 shares, described as a "Share Option (Right to Buy)" at an exercise price of $0.0000 per share. These options were awarded as a grant or other acquisition.
The option vests in twelve substantially equal monthly installments over a one-year period starting on February 21, 2026. Any remaining unvested portion will vest on the day immediately preceding the next annual meeting of shareholders following the grant date, as long as he continues in service through each vesting date.
Zura Bio Ltd director Parvinder Thiara reported receiving a share option award covering 38,823 Class A Ordinary Shares. The option, with a conversion or exercise price of $6.36 per share, was granted on January 23, 2026 and is held directly.
The option vests in twelve substantially equal monthly installments over a one-year period starting January 23, 2026. Any remaining unvested portion will vest on the day immediately preceding the next annual meeting of shareholders following the grant date, subject to Thiara’s continued service on each vesting date.
Zura Bio Ltd reported that Chief Executive Officer and director Sandeep Chidambar Kulkarni received an employee stock option grant on January 21, 2026. The option covers 2,934,107 Class A Ordinary Shares at an exercise price of $6.32 per share and expires on January 21, 2036.
According to the vesting terms, one fourth of the options will vest on January 21, 2027, and the remaining options will vest in equal quarterly installments, with one twelfth of the remaining shares vesting each quarter. Vesting is conditioned on the CEO’s continuous service with the company.